Company Profile
Halozyme Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- HALO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
106.94 USD (-3.13%)
Close
Last updated: October 1, 2026
7.86B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, HALO closed down 3.13% at $106.94. No new same-company headline was identified in the current news window.
Company overview
Drug-Delivery Technology Company
Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered. Its business is based on platform access fees, development milestones, product supply, and royalties from partner medicines rather than ownership of most underlying therapeutic molecules.
ENHANZE Platform
ENHANZE uses recombinant human hyaluronidase PH20 to temporarily degrade hyaluronan in the subcutaneous space. This can enable large-volume subcutaneous delivery of therapies that would otherwise require intravenous infusion, reducing administration time and treatment burden.
Commercial Partner Products
The technology is incorporated into multiple marketed partner products, including subcutaneous formulations in oncology, immunology, and rare disease. Products such as DARZALEX SC and VYVGART Hytrulo generate recurring royalty revenue while partners retain responsibility for clinical development and commercialization.
Hypercon and High-Concentration Formulations
The Hypercon platform is designed to create highly concentrated biologic formulations that may support lower injection volumes and more flexible administration. Halozyme is pursuing multi-target collaborations to establish Hypercon as a complementary solution for medicines that cannot be optimally delivered with conventional formulations.
Expanded Injectable Technologies
Acquisitions of Antares Pharma, Elektrofi, and Surf Bio have broadened Halozyme into autoinjectors, wearable delivery systems, microparticle suspensions, and additional formulation technologies. The resulting portfolio addresses both volume and concentration constraints across subcutaneous and self-administered medicines.
Future catalysts
Recent news
- 01
- 02
- 03
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Halozyme Therapeutics, Inc. (HALO)?
Halozyme Therapeutics, Inc. (HALO) most recently closed at 106.94 USD, a -3.13% move versus the previous session.
What is the market cap of Halozyme Therapeutics, Inc. (HALO)?
Halozyme Therapeutics, Inc. currently has a market capitalization of 7.86B USD on BioPharmSignal.
What does Halozyme Therapeutics, Inc. do?
Drug-Delivery Technology Company Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered. Its business is based on platform access fees, development milestones, product supply, and royalties from partner medicines rather than ownership of most underlying therapeutic molecules. ENHANZE Platform ENHANZE...
On which exchange is HALO stock listed?
Halozyme Therapeutics, Inc. (HALO) is associated with NASDAQ, United States, Biopharma.
What is Drug-Delivery?
Drug-Delivery Technology Company Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered.
Which conditions is Halozyme Therapeutics, Inc. targeting with Drug-Delivery?
Halozyme Therapeutics, Inc. is associated with oncology, immunology, rare disease based on its company overview and current catalyst commentary.
What is Technology?
Drug-Delivery Technology Company Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered.
What is Halozyme?
Drug-Delivery Technology Company Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered.